CTB001
Source CTB001 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
CTB001 is a recently developed generic version of the anticoagulant bivalirudin. In a phase‑1, single‑dose, dose‑escalation study involving 24 healthy Korean men, its pharmacokinetic (PK) profile and pharmacodynamic (PD) effects on clotting times were characterized using population modelling and simulation. The data provide an initial understanding of how CTB001 behaves in the body and its impact on laboratory measures of coagulation, informing future dosing considerations.
Mechanism of Action
CTB001, like its reference product bivalirudin, acts as a direct thrombin inhibitor. By binding to the active site of thrombin, it prevents conversion of fibrinogen to fibrin, thereby prolonging clotting assays such as activated partial thromboplastin time (aPTT), prothrombin time (PT) and thrombin time (TT). The abstract reports dose‑dependent increases in these laboratory parameters, reflecting inhibition of thrombin‑mediated coagulation pathways.
What the Research Shows
The only peer‑reviewed source is a 2019 Pharm Res. article reporting a randomized, double‑blind, placebo‑controlled, single‑dose, dose‑escalation phase‑1 trial in 24 healthy Korean male volunteers. Population PK analysis identified a three‑compartment linear model with a saturable peripheral binding site. PD modelling showed clear dose‑response relationships for aPTT, PT (both INR and seconds), and TT, with a simple maximum‑effect model best describing most endpoints. Monte‑Carlo simulations estimated that the maximal prolongation of aPTT lasted about 52.1 seconds. No clinical efficacy or safety outcomes in patients were presented.
Reported Benefits
The study demonstrates that CTB001 exhibits predictable PK characteristics and a dose‑dependent PD effect on standard coagulation assays, suggesting it can achieve controllable anticoagulation similar to bivalirudin. The modelling approach provides a framework for exploring optimal dosing regimens in future clinical investigations.
Limitations of the Evidence
Evidence is limited to a single, small phase‑1 trial in healthy male subjects; no data are available on patients with cardiovascular disease, repeated dosing, or long‑term safety. The abstract does not report comparative efficacy versus the reference product, nor does it disclose adverse event rates. Consequently, the clinical relevance of the PK/PD findings remains uncertain.
Safety Considerations
The abstract mentions that CTB001 has shown good safety in clinical trials, but the phase‑1 study described only includes healthy volunteers and provides no detailed adverse‑event data. Thus, safety conclusions are preliminary, and potential bleeding risks or other thrombin‑inhibition–related effects have not been characterized in patient populations.
How It Is Administered
The abstract does not specify the route of administration or formulation used in the study. As a generic of bivalirudin, CTB001 is likely intended for parenteral use, but the exact delivery method (e.g., intravenous infusion) is not described in the source material.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleModerateHan S, et al.2019-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of drug is CTB001?
CTB001 is a generic formulation of bivalirudin, a direct thrombin inhibitor used as an anticoagulant. The available study examined its pharmacokinetics and pharmacodynamics in healthy volunteers.
How does CTB001 affect blood clotting tests?
In the phase‑1 trial, increasing doses of CTB001 produced dose‑dependent prolongation of aPTT, PT (both INR and seconds) and thrombin time, indicating inhibition of thrombin activity and reduced clot formation in laboratory assays.
Has CTB001 been tested in patients with heart disease?
No. The published data are limited to a single‑dose study in healthy male participants. Clinical efficacy, safety, and dosing in patients with cardiovascular conditions have not yet been reported.
Is CTB001 approved for clinical use?
The abstract notes that CTB001 is a newly developed generic of the FDA‑approved drug bivalirudin, but it does not provide information on regulatory approval status for CTB001 itself.
What are the known safety concerns with CTB001?
Safety information is limited to the phase‑1 study, which did not report detailed adverse events. As a thrombin inhibitor, potential bleeding risk is a theoretical concern, but specific safety data for CTB001 are not available.
What is CTB001?
CTB001 is a recently developed generic version of the anticoagulant bivalirudin. In a phase‑1, single‑dose, dose‑escalation study involving 24 healthy Korean men, its pharmacokinetic (PK) profile and pharmacodynamic (PD) effects on clotting times were characterized using population modelling and simulation. The data provide an initial understanding of how CTB001 behaves in the body and its impact on laboratory measures of coagulation, informing future dosing considerations.